Glenmark's Swiss subsidiary has completed phase I clinical trials for a pain reliever, GRC 6211, and is planning to launch the
molecule in 2011. GRC 6211 is an antagonist compound for a range of pain indications like osteoarthritis, urinary incontinence and naturopathic pain.
Glenmark is in discussions with the potential partners for licensing this compound. Pain management has a large unmet market and companies are trying to capture this large market. Merck, GSK and Pfizer also have molecules under development in the same category.
|
